By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates in development. Its products are produced and … Read more
By M. Marin NASDAQ:AEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding clinical trial has been treated with the Hemopurifier. The trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. In other words, the trial is evaluating the Hemopurifier … Read more
By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced results for the year ended October 31, 2024. The headline revenue and earnings releases were below expectations quarter, but management issued comments regarding future prospects that have us optimistic that the trend of decreasing revenue will soon be reversed. Management … Read more
By Thomas Kerr, CFA NASDAQ:SPGC READ THE FULL SPGC RESEARCH REPORT On January 27, 2025, Sacks Parente Golf (NASDAQ:SPGC) provided preliminary financial results for the 4th quarter of 2024 and full year 2024. Revenue is expected to be between $1.1 million – $1.3 million in the 4th quarter of 2024, an increase of 882% … Read more
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths … Read more
